We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.12%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$23.6B
AUM Growth
+$1.71B
Cap. Flow
-$406M
Cap. Flow %
-1.72%
Top 10 Hldgs %
52.37%
Holding
196
New
43
Increased
37
Reduced
38
Closed
21

Top Buys

Rank Stock Value
1
HES
Hess
HES
+$502M
2
UNH icon
UnitedHealth
UNH
+$254M
3
ABNB icon
Airbnb
ABNB
+$243M
4
AON icon
Aon
AON
+$196M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$152M

Top Sells

Rank Stock Value
1
CHTR icon
Charter Communications
CHTR
+$311M
2
TMO icon
Thermo Fisher Scientific
TMO
+$228M
3
BX icon
Blackstone
BX
+$222M
4
TRU icon
TransUnion
TRU
+$203M
5
SPLK
Splunk Inc
SPLK
+$202M

Sector Composition

Rank Sector Weight
1 Healthcare 26.88%
2 Technology 10.2%
3 Financials 8.76%
4 Energy 8.1%
5 Industrials 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEKE icon
51
KE Holdings
BEKE
$19.6B
$65.1M 0.28%
4,740,833
-17,667
-0.4% -$247K
LBPH
52
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$63.5M 0.27%
2,940,500
+1,380,000
+88% +$30.1M
ICLR icon
53
Icon
ICLR
$13.3B
$60.4M 0.26%
+179,700
New +$53M
EDU icon
54
New Oriental
EDU
$8.88B
$53.4M 0.23%
615,000
+602,000
+4,631% +$51.1M
XBI icon
55
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.2B
$47.4M 0.2%
+500,000
New +$46.4M
CERE
56
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$44.9M 0.19%
1,063,000
+495,679
+87% +$20.8M
BHVN icon
57
Biohaven
BHVN
$2.09B
$43.7M 0.19%
799,000
+49,000
+7% +$2.43M
ENTA icon
58
Enanta Pharmaceuticals
ENTA
$392M
$36.6M 0.16%
2,095,000
+70,000
+3% +$926K
EVH icon
59
Evolent Health
EVH
$536M
$34M 0.14%
1,037,331
-1,126,578
-52% -$36M
IONS icon
60
Ionis Pharmaceuticals
IONS
$9.93B
$31.8M 0.14%
734,000
-821,020
-53% -$39.1M
LQDA icon
61
Liquidia Corp
LQDA
$6.14B
$30.3M 0.13%
+2,055,000
New +$28.6M
HIMS icon
62
Hims & Hers Health
HIMS
$7.88B
$25.9M 0.11%
1,676,000
+1,634,000
+3,890% +$18.4M
PCVX icon
63
Vaxcyte
PCVX
$9.32B
$25.8M 0.11%
377,400
+374,000
+11,000% +$25.9M
UTHR icon
64
United Therapeutics
UTHR
$22B
$25.3M 0.11%
110,000
-366,000
-77% -$82.6M
GERN icon
65
Geron
GERN
$977M
$24.7M 0.1%
+7,495,000
New +$16.8M
BABA icon
66
Alibaba
BABA
$286B
$23.8M 0.1%
329,000
-206,000
-39% -$15.1M
PGNY icon
67
Progyny
PGNY
$1.97B
$22.6M 0.1%
+592,600
New +$22.4M
VYGR icon
68
Voyager Therapeutics
VYGR
$209M
$21.3M 0.09%
2,292,000
+1,000,000
+77% +$8.44M
PCG icon
69
PG&E
PCG
$38.8B
$21.3M 0.09%
1,271,642
-1,000,000
-44% -$16.8M
DFS
70
DELISTED
Discover Financial Services
DFS
$21M 0.09%
+160,000
New +$18.3M
APGE icon
71
Apogee Therapeutics
APGE
$10.2B
$20.3M 0.09%
+305,000
New +$13.3M
ELEV
72
DELISTED
Elevation Oncology
ELEV
$19.9M 0.08%
+3,886,663
New +$12.6M
HUM icon
73
Humana
HUM
$45.5B
$17.9M 0.08%
51,700
-69,644
-57% -$26.4M
SYRE icon
74
Spyre Therapeutics
SYRE
$9.39B
$17.7M 0.08%
+466,000
New +$13.5M
ARQT icon
75
Arcutis Biotherapeutics
ARQT
$3.15B
$17.6M 0.07%
+1,780,000
New +$13.3M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2024 Portfolio in Review

As of Q1 2024, Thomas Steyer held 196 positions worth $23.6B, up 7.8% from $21.9B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Thomas Steyer's Q1 2024 filing shows 43 new, 37 increased, 38 reduced and 21 closed positions. Its largest new stake was Airbnb: 1,608,220 shares worth $265M. The largest sale was Charter Communications, an estimated $311M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 27% a quarter earlier, followed by Technology and Financials.

  • Thomas Steyer's largest Q1 2024 buy was Airbnb: 1,608,220 shares worth $265M.
  • Thomas Steyer added most to Hess in Q1 2024, an estimated $502M increase.
  • Thomas Steyer's biggest Q1 2024 reduction was Thermo Fisher Scientific, cutting an estimated $228M.
  • Thomas Steyer fully exited Charter Communications in Q1 2024, selling an estimated $311M.
  • Thomas Steyer's ten largest holdings make up 52% of its $23.6B portfolio in Q1 2024.
  • Thomas Steyer opened 43 new positions and closed 21 in Q1 2024.
  • Thomas Steyer's portfolio value rose 7.8% quarter-over-quarter to $23.6B.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.